Every material Form 8-K Steris filed with the SEC in 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
On November 4, 2026, STERIS and its subsidiaries entered a new $1.6 billion revolving credit facility that replaces the existing credit agreement dated October 7, 2024, and a separate delayed draw term loan of up to $500 million. The term loan can be drawn only if STERIS completes its acquisition of Xodus Medical, Inc. For shareholders, the filing adds committed borrowing capacity tied to that acquisition, and the filing does not state the acquisition price or the amount that will be borrowed.
Revolving credit facility of $1,600 million matures on November 4, 2031, with an incremental increase of up to $800 million available.
Delayed draw term loan of up to $500 million can be used only after the Xodus Medical Acquisition is consummated and terminates if that deal is validly terminated or the outside date occurs.
Term loan matures five years after the acquisition closing date; no principal is due in year one, then 1.25% quarterly in years two and three and 1.875% quarterly in years four and five.
No borrowings were incurred to refinance the existing credit agreement at closing, and all term loan lenders are also lenders under the revolver.
STERIS plc reported total revenue of $1.6 billion for the second quarter of fiscal 2027, representing a 9% increase compared to the prior year period. Net income rose to $213.7 million, and the company updated its full-year adjusted EPS outlook to a range of $11.35 to $11.55.
Total revenue for Q2 fiscal 2027 reached $1.6 billion, up 9% year-over-year.
Diluted EPS as reported was $2.19, while adjusted diluted EPS increased to $2.94.
Full-year fiscal 2027 adjusted EPS outlook was raised to a range of $11.35 to $11.55.
The company approved a targeted restructuring plan anticipating total charges of approximately $45 million.
STERIS, through subsidiary STERIS Corporation, agreed on October 11, 2026 to acquire Xodus Medical, a Pennsylvania specialty surgical products business, for $2.1 billion in cash at closing, with up to $150 million more tied to calendar 2028 performance targets. The deal is expected to be financed mainly with debt, backed by a $2.0 billion bridge financing commitment, and is expected to close by December 31, 2026, subject to regulatory approvals.
Cash price: $2.1 billion at closing, subject to customary adjustments, plus up to $150 million in earnout tied to calendar 2028 targets
Financing: expected to be funded primarily with debt; $2.0 billion senior unsecured bridge facility from JPMorgan Chase Bank and Goldman Sachs Bank USA
Timing: expected to close by December 31, 2026; either party may terminate if not closed by July 12, 2027, extendable to January 11, 2028
STERIS reported fiscal 2027 first-quarter revenue up 7% to $1.5 billion and diluted EPS of $2.04, up from $1.79, with adjusted EPS of $2.59 versus $2.34. It reiterated its full-year revenue and adjusted EPS guidance, but raised its capital expenditure outlook and lowered its free cash flow outlook, and it announced a consolidation of U.S. chemistries manufacturing that includes closing facilities in St. Louis, Missouri, and Plymouth, Minnesota.
Q1 fiscal 2027 revenue rose 7% to $1.5 billion; Healthcare revenue grew 8% to $1.05 billion.
Free cash flow fell to $279.6 million from $326.5 million; operating cash flow was $367.1 million versus $420.0 million.
Expected pre-tax restructuring charges of $55 million to $70 million, with completion anticipated during fiscal 2030.
Full-year free cash flow outlook cut to about $800 million from $850 million, while capital expenditures are now expected at about $450 million versus $375 million.
STERIS reported fiscal 2026 revenue from continuing operations up 9% to $5.9 billion, with reported diluted EPS from continuing operations rising to $7.93 from $6.16. The board approved a new $1 billion share repurchase program and guided fiscal 2027 adjusted EPS to $11.10 to $11.30, which would be an increase of 9% to 11% over fiscal 2026 adjusted EPS of $10.17.
Full-year revenue from continuing operations was $5.9 billion, up from $5.5 billion, with constant currency organic growth of 7%.
Reported diluted EPS from continuing operations was $7.93 versus $6.16; adjusted EPS was $10.17 versus $9.22.
Fiscal 2027 outlook calls for revenue growth of 7-8% and free cash flow of about $850 million.
The new $1 billion buyback replaces the prior authorization and may be suspended or discontinued at any time.
STERIS plc appointed Pierre Boulud, CEO of bioMérieux, to its Board of Directors effective May 5, 2026, and increased the Board from nine to ten members. Director Richard C. Breeden, who has served 18 years, will not stand for reelection at the 2026 Annual General Meeting, and the company said his decision was not due to any disagreement with the company. The filing reports no financial results or guidance changes, so the event mainly affects board composition.
Pierre Boulud was appointed director effective May 5, 2026; the Board increased from nine to ten members.
Richard C. Breeden notified the company on May 1, 2026 that he will not stand for reelection at the 2026 Annual General Meeting, after 18 years as a director.
Boulud has been CEO of bioMérieux since June 2023 and will receive a prorated fee of $76,989 for the rest of the 2025-26 term, paid in career restricted stock units.
STERIS plc amended the transition agreement with former Chief Financial Officer Michael J. Tokich, dated August 5, 2025, on March 31, 2026. Mr. Tokich will serve as a part-time senior financial advisor from April 1, 2026 through March 31, 2027, at a reduced base salary of $60,000 and without his health, dental and other employee benefits. The change affects one former executive's compensation and does not alter the company's reported results or guidance.
Amendment dated March 31, 2026 modifies the August 5, 2025 Transition Agreement with former CFO Michael J. Tokich
Part-time senior financial advisor role runs April 1, 2026 through March 31, 2027
Annual base salary reduced to $60,000 during the extended period; health, dental, life insurance and other benefit plans no longer apply
Cash bonus is possible at the CEO's discretion, subject to approval by the Compensation and Organization Development Committee
STERIS reported fiscal 2026 third-quarter results for the quarter ended December 31, 2025, with revenue up 9% to $1.5 billion and diluted EPS from continuing operations of $1.96, compared with $1.75 a year earlier. The company kept its fiscal 2026 adjusted EPS outlook of $10.15 to $10.30, but raised its estimate of the tariff hit to pre-tax profit to approximately $55 million from approximately $45 million.
Q3 revenue from continuing operations was $1,496.2 million, up from $1,370.6 million; constant currency organic growth was 8%.
Q3 diluted EPS from continuing operations was $1.96 versus $1.75; adjusted EPS was $2.53 versus $2.32.
Fiscal 2026 outlook was maintained: adjusted EPS of $10.15 to $10.30 and revenue growth of 8% to 9%.
Estimated tariff impact on pre-tax profit rose to approximately $55 million from approximately $45 million.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Steris filing is on SEC EDGAR ↗. 8-K briefs of other companies →